<DOC>
	<DOCNO>NCT00003549</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine cyclophosphamide , methotrexate , fluorouracil treat patient Merkel cell cancer .</brief_summary>
	<brief_title>S9716 : Combination Chemotherapy Treating Patients With Merkel Cell Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Investigate ability Southwest Oncology Group Melanoma Committee enroll patient unresectable Merkel cell carcinoma local-regional metastatic . II . Determine overall survival rate objective response rate patient treatment cyclophosphamide , methotrexate , fluorouracil . OUTLINE : Patients stratify accord local-regional disease versus metastatic disease . Patients receive cyclophosphamide IV , methotrexate IV , fluorouracil IV day 1 . Courses repeat every 21 day 2 year absence disease progression unacceptable toxicity . Patients follow every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 80 patient ( 40 patient per stratum ) accrue study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven unresectable Merkel cell carcinoma Localregional OR Metastatic Bidimensionally measurable disease If know sit previously irradiate , disease must progressive CNS metastasis allow site measurable disease No pleural effusion ascites PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1500/mm3 Platelet count least 100,000/mm3 Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception No prior malignancy within 5 year except : Adequately treat basal cell squamous cell skin cancer Adequately treat stage I II cancer In situ cervical cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy immunotherapy No concurrent immunotherapy Chemotherapy : No prior chemotherapy metastatic disease At least 4 week since prior adjuvant chemotherapy No prior adjuvant cyclophosphamide , methotrexate , fluorouracil No concurrent chemotherapy Endocrine therapy : No concurrent hormone therapy Radiotherapy : See Disease Characteristics At least 14 day since prior radiotherapy Surgery : At least 2 week since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage II neuroendocrine carcinoma skin</keyword>
	<keyword>stage III neuroendocrine carcinoma skin</keyword>
	<keyword>recurrent neuroendocrine carcinoma skin</keyword>
</DOC>